Management of Hypertension, Hypercholesterolemia, and Renal Dysfunction

Blood Pressure Management

• The American Heart Association recommends starting with an ACE inhibitor or ARB as first-line therapy for hypertension in patients with evidence of renal dysfunction, with a target blood pressure of 120-129/70-79 mmHg to reduce cardiovascular risk 1, 4, 5
• The European Society of Cardiology suggests adding a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic if blood pressure remains uncontrolled 5, 4
• Monitoring renal function and serum potassium levels within 2-4 weeks after initiating ACE inhibitor or ARB therapy is recommended by the American Journal of Kidney Diseases 1

Lipid Management

• The American College of Cardiology recommends initiating statin therapy for patients with an LDL of 125 mg/dL or higher, with a target LDL of <100 mg/dL 1, 7
• The European Heart Journal suggests monitoring lipid levels 8 (±4) weeks after starting treatment to assess efficacy 6
• Checking liver enzymes before treatment and 8-12 weeks after starting therapy is recommended by the European Heart Journal 6

Renal Function Management

• The National Kidney Foundation recommends evaluating the cause of elevated BUN/creatinine ratio and monitoring GFR and serum creatinine regularly, with follow-up every 1-6 months if GFR <60 mL/min/1.73 m² 1
• The Kidney International journal suggests avoiding nephrotoxic medications such as NSAIDs and counseling patients to temporarily hold ACE inhibitor/ARB and diuretics when at risk for volume depletion 1, 2, 8

Hypoglycemia Management

• The American Family Physician recommends investigating the cause of hypoglycemia and ruling out medication-induced hypoglycemia, as well as providing education on recognizing and managing hypoglycemic symptoms 9

Lifestyle Modifications

• The American Heart Association recommends restricting dietary sodium to <2.0 g/day and encouraging regular physical activity, at least 150 minutes of moderate-intensity aerobic activity per week 1, 2, 3, 8
• The European Heart Journal suggests advising weight normalization if overweight or obese and recommending smoking cessation if applicable 2, 8

Monitoring and Follow-up

• The American Journal of Kidney Diseases recommends monitoring blood pressure frequently until controlled, then every 3-6 months, as well as evaluating renal function and electrolytes 2-4 weeks after starting ACE inhibitor/ARB therapy 1, 3
• The Diabetes Care journal suggests checking orthostatic blood pressure measurements to assess for autonomic neuropathy 10